Biohit Oyj
OMXH:BIOBV
Biohit Oyj
Net Income (Common)
Biohit Oyj
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Biohit Oyj
OMXH:BIOBV
|
Net Income (Common)
€2.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
R
|
Revenio Group Oyj
OMXH:REG1V
|
Net Income (Common)
€18.5m
|
CAGR 3-Years
2%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
M
|
Modulight Oyj
OMXH:MODU
|
Net Income (Common)
-€11.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bioretec Oy
OMXH:BRETEC
|
Net Income (Common)
-€3.7m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
O
|
Optomed Oyj
OMXH:OPTOMED
|
Net Income (Common)
-€5.5m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
N
|
Nexstim Oyj
OMXH:NXTMH
|
Net Income (Common)
-€833.1k
|
CAGR 3-Years
40%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
Biohit Oyj
Glance View
Biohit Oyj engages in the development, manufacture, and market of diagnostic tests and analysis systems. The company is headquartered in Helsinki, Etela-Suomen. The firm operates one business segment, named Diagnostics. The Diagnostics segment offers solutions for the early diagnosis and prevention of gastrointestinal diseases. The company provides blood-sample examination based on GastroPanel for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, as well as the ColonView examination for the early detection of fecal occult intestinal bleeding, which indicates a risk of colorectal cancer. The Company’s products are used in hospitals, healthcare centers and research institutions. The company operates primarily in Europe and Asia. Furthermore, the Company is a parent of Biohit Healthcare Ltd, Biohit Healthcare Srl, Oy Finio Ab, and Vantaan Hienomekano Oy, among others.
See Also
What is Biohit Oyj's Net Income (Common)?
Net Income (Common)
2.6m
EUR
Based on the financial report for Dec 31, 2024, Biohit Oyj's Net Income (Common) amounts to 2.6m EUR.
What is Biohit Oyj's Net Income (Common) growth rate?
Net Income (Common) CAGR 1Y
40%
Over the last year, the Net Income (Common) growth was 40%.
You don't have any saved screeners yet